The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.

The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.

OBJECTIVE: To assess the cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia, as implementation at the local health centre level has yet to be undertaken in many resource-limited countries despite recommendations in recent updated World Health Organization (WHO) guidel...

Full description

Bibliographic Details
Main Authors:	Ryan, M, Griffin, S, Chitah, B, Walker, A, Mulenga, V, Kalolo, D, Hawkins, N, Merry, C, Barry, MG, Chintu, C, Sculpher, M, Gibb, D
Format:	Journal article
Language:	English
Published:	2008

Similar Items

Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis.
by: Prendergast, A, et al.
Published: (2011)

The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children.
by: Walker, A, et al.
Published: (2007)

Adherence to both cotrimoxazole and placebo is associated with improved survival among HIV-infected Zambian children.
by: Walker, A, et al.
Published: (2009)

National policy development for cotrimoxazole prophylaxis in Malawi, Uganda and Zambia: the relationship between Context, Evidence and Links
by: Chishinga Nathaniel, et al.
Published: (2011-06-01)

Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.
by: Mulenga, V, et al.
Published: (2007)

Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia.
by: Mwenya, D, et al.
Published: (2010)

Costing of Paediatric Treatment alongside Clinical Trials under Low Resource Constraint Environments: Cotrimoxazole and Antiretroviral Medications in Children Living with HIV/AIDS
by: Bona M. Chitah
Published: (2016-01-01)

Cotrimoxazole prophylaxis for infants exposed to HIV infection
by: Stephen M. Graham

Cotrimoxazole prophylaxis for infants exposed to HIV infection
by: Stephen M. Graham
Published: (2004-04-01)

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
by: Prendergast, A, et al.
Published: (2016)

Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection
by: Gill Christopher J., et al.
Published: (2004-01-01)

Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.
by: Christopher J Hoffmann, et al.
Published: (2014-01-01)

Linking HIV-infected TB patients to cotrimoxazole prophylaxis and antiretroviral treatment in India.
by: Neeraj Raizada, et al.
Published: (2009-06-01)

Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries?
by: Anna Coutsoudis, et al.

Time for new recommendations on cotrimoxazole prophylaxis for HIV-exposed infants in developing countries?
by: Anna Coutsoudis, et al.
Published: (2010-12-01)

Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China
by: Wei Cheng, et al.

Factors associated with coverage of cotrimoxazole prophylaxis in HIV-exposed children in South Africa.
by: Dhayendre Moodley, et al.
Published: (2013-01-01)

Co-trimoxazole prophylaxis in African children with HIV-1 - Reply
by: Gibb, D, et al.
Published: (2005)

Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants.
by: Scott Dryden-Peterson, et al.
Published: (2013-01-01)

Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
by: Mulenga, V, et al.
Published: (2010)

Cotrimoxazole Prophylaxis Specifically Selects for Cotrimoxazole Resistance in Streptococcus mutans and Streptococcus sobrinus with Varied Polymorphisms in the Target Genes folA and folP
by: Buwembo William, et al.
Published: (2012-01-01)

Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi
by: Mwaungulu Frank B.D., et al.
Published: (2004-01-01)

Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
by: Ellis, J, et al.
Published: (2007)

Impact of Anti-Retroviral Treatment and Cotrimoxazole Prophylaxis on Helminth Infections in HIV-Infected Patients in Lambaréné, Gabon.
by: Saskia Janssen, et al.
Published: (2015-05-01)

Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
by: Oudijk, J, et al.
Published: (2012)

Cotrimoxazole-Induced Hypoglycemia in an HIV-Infected Patient
by: Christine A Hughes, et al.
Published: (2001-01-01)

A cost-effectiveness analysis of artemether lumefantrine for treatment of uncomplicated malaria in Zambia
by: Hawela Moonga, et al.
Published: (2007-02-01)

Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.
by: Chintu, C, et al.
Published: (2004)

Ten years of surveillance for invasive Streptococcus pneumoniae during the era of antiretroviral scale-up and cotrimoxazole prophylaxis in Malawi.
by: Dean B Everett, et al.
Published: (2011-03-01)

Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation
by: Bourke, CD, et al.
Published: (2019)

Usefulness of rapid diagnostic test in the diagnosis of asymptomatic malaria in HIV infected children on cotrimoxazole prophylaxis in Benin City, Nigeria
by: Ibadin MO, et al.
Published: (2024-07-01)

Increased malaria parasitaemia among adults living with HIV who have discontinued cotrimoxazole prophylaxis in Kitgum district, Uganda.
by: Philip Orishaba, et al.
Published: (2020-01-01)

The Patterns of Primary Cotrimoxazole Prophylaxis in Adult HIV Patients in HIV Integrated Clinic Cipto Mangunkusumo Hospital Jakarta in 2004-2013
by: Ken Ayu Mastini, et al.
Published: (2017-12-01)

Effects of cotrimoxazole prophylaxis on Talaromyces marneffei infection in HIV/AIDS patients receiving antiretroviral therapy: a retrospective cohort study
by: Junjun Jiang, et al.
Published: (2019-01-01)

Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial.
by: Christina S Polyak, et al.
Published: (2016-01-01)

Does cotrimoxazole prophylaxis in HIV patients increase the drug resistance of pneumococci? A comparative cross-sectional study in southern Ethiopia.
by: Mohammed Seid, et al.
Published: (2020-01-01)

Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial.
by: Walker, A, et al.
Published: (2006)

The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis.
by: Dennis W Juma, et al.
Published: (2019-03-01)

Examining gender differentials and determinants of private health insurance coverage in Zambia
by: James Mulenga, et al.
Published: (2021-11-01)

Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial.
by: Raquel González, et al.
Published: (2014-09-01)